



SDI Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_50134
Title of the Manuscript:	Quantitative Structure Activity Relationship of new Isatin analogues as anti-breast cancer agent by different chemometrics tools
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	Depending on the most effective methods used to identify the QSAR of statin compound derivatives which compound (s) showed the highest activity as anticancer agent? Any practical procedure of these compounds on breast cancer cell line to emphasize the authors' assumption?	
Minor REVISION comments	The facility where the work has been conducted should be provided (faculty and department) Pay attention to punctuation .	
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	

Reviewer Details:

Name:	Heba Gamal Abd El-Aziz Nasr
Department, University & Country	Al-Azhar University, Egypt